主要目的：以白云山东泰商丘药业有限公司生产的盐酸米那普仑片（规格：25 mg）为受试制剂，按生物等效性试验的有关规定，与旭化成ファーマ株式会社持证的盐酸米那普仑片为参比制剂（商品名：Toledomin，规格：25 mg），对比在健康人体内的相对生物利用度，研究两制剂的人体生物等效性。次要目的：观察盐酸米那普仑片受试制剂和参比制剂（Toledomin）在健康受试者中的安全性。

开始日期2025-02-18

申办/合作机构

白云山东泰商丘药业有限公司

ChiCTR2400083771

N/AIIT

Randomized, double-blind, and placebo-controlled clinical study of Milnacipran hydrochloride tablets combined with transcranial magnetic stimulation in the treatment of somatic cough disorders

开始日期2024-05-01

申办/合作机构

上海市同济医院

[+1]

CTR20223361

/ CompletedN/A

盐酸米那普仑片在健康受试者中的随机、开放、单次给药、两制剂、两周期人体生物等效性研究

采用单中心、随机、开放、两周期、自身交叉、单剂量空腹及餐后给药试验设计评价上海现代制药股份有限公司生产的盐酸米那普仑片（规格：50mg）与日本旭化成株式会社生产的盐酸米那普仑片（商品名：Toledomin®，参比制剂，50mg）在健康人群空腹、餐后口服的生物等效性，为上海现代制药股份有限公司生产的盐酸米那普仑片与日本旭化成株式会社生产的盐酸米那普仑片临床疗效的一致性提供证据。

开始日期2023-02-01

申办/合作机构

上海现代制药股份有限公司

100 项与盐酸米那普仑相关的临床结果

登录后查看更多信息

100 项与盐酸米那普仑相关的转化医学

登录后查看更多信息

100 项与盐酸米那普仑相关的专利（医药）

登录后查看更多信息

772

项与盐酸米那普仑相关的文献（医药）

2025-08-01·RHEUMATOLOGY

Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis

Review

作者: Kelleher, Eoin M ; Amarnani, Raj ; Pathak, Anna ; Wall, Amanda ; Murphy, Robert ; Irani, Anushka ; Fordham, Beth ; Lee, Hopin ; Brennan, Isabelle

Abstract:

Objectives:

Sleep disturbance is a key symptom of fibromyalgia and a risk factor for chronic widespread pain. This systematic review and meta-analysis aims to assess the effectiveness of pharmacological treatments and cognitive behavioural therapy (CBT) in improving sleep quality in fibromyalgia patients.

Methods:

A systematic search of PubMed, MEDLINE, Embase, Cochrane CENTRAL and CINAHL was conducted for randomized controlled trials (RCTs) published up to April 2023. Studies assessing pharmacological or CBT interventions with sleep-related outcomes were included. Data were extracted, and meta-analyses were performed where applicable. Study quality and bias were evaluated using the Cochrane Risk of Bias tool.

Results:

Forty-seven RCTs, including 11 094 participants, were reviewed. CBT for insomnia (CBT-I) showed a significant improvement in sleep quality (SMD −0.63, 95% CI −0.98 to −0.27), while CBT for pain (CBT-P) had no significant impact. Pharmacological agents such as pregabalin and sodium oxybate moderately improved sleep, but there was uncertainty around this evidence. Amitriptyline, milnacipran and duloxetine showed no significant benefit for sleep. Study heterogeneity was moderate, and no publication bias was detected.

Conclusion:

CBT-I is a promising treatment for enhancing sleep quality in fibromyalgia. Pharmacological treatments like pregabalin may be beneficial but should be used cautiously due to potential risks. Future research should prioritize trials focusing on sleep as a primary outcome and explore the comparative effectiveness of pharmacological treatments and CBT-I in fibromyalgia. Understanding the mechanisms linking sleep and fibromyalgia will also help guide future therapies.

2025-08-01·JAMA Psychiatry

Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression

Article

作者: Modesti, Martina Nicole ; Simmaco, Maurizio ; Spirito, Sara ; Preissner, Robert ; Arena, Jan Francesco ; Del Casale, Antonio ; Ferracuti, Stefano ; Borro, Marina ; Gentile, Giovanna ; Preissner, Saskia

Importance:

Treatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, a rapid-acting antidepressant, is usually combined with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), but comparative evidence of these combinations’ effectiveness in real-world settings is sparse.

Objective:

To determine whether the combination of esketamine + SNRI shows differences in clinical outcomes compared to esketamine + SSRI in patients with TRD.

Design, Setting, and Participants:

This retrospective cohort study was conducted in September 2024 using data from the TriNetX global health research network, with a 5-year time window from the first esketamine trial. TriNetX data are drawn from real-world clinical settings and use electronic medical records from more than 90 health care centers across 20 countries. Adults with TRD who were treated with esketamine combined with either an SSRI or an SNRI were eligible for inclusion.

Exposure:

Treatment with esketamine combined with an SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or vilazodone) or an SNRI (desvenlafaxine, duloxetine, levomilnacipran, milnacipran, or venlafaxine).

Main Outcomes and Measures:

The primary outcomes were all-cause mortality, hospitalization, depression relapse, and suicide attempts. Kaplan-Meier survival analysis was used to estimate survival probabilities, while risk ratios and odds ratios were calculated for all outcomes.

Results:

In a population-based sample of 61 882 adult participants with TRD who were treated with esketamine combined with either an SSRI or an SNRI, 55 480 participants were selected after applying propensity score matching for age and sex. These patients were divided into 2 matched cohorts: 27 740 patients treated with esketamine + SSRI (16 007 female participants [57.7%]; mean [SD] age, 46.0 [21.3] years) and 27 740 treated with esketamine + SNRI (16 242 female participants [58.6%]; mean [SD] age, 45.9 [21.9] years). In the entire study population, the incidence of mortality, hospitalizations, depressive relapses, and suicide attempts was low throughout the study period. Patients in the esketamine + SNRI group had significantly lower all-cause mortality (5.3% vs 9.1%; P &lt; .001), hospitalization rates (0.1% vs 0.2%; P &lt; .001), and depression relapses (14.8% vs 21.2%; P &lt; .001) compared to the esketamine + SSRI group, which instead showed a lower incidence of suicidal attempts (0.3% vs 0.5%; P = .04).

Conclusions and Relevance:

In this retrospective comparative effectiveness study, among the study sample, incidence of mortality, hospitalizations, depressive relapses, and suicide attempts was low. The esketamine + SNRI group showed lower incidence of mortality, hospitalizations, and depressive relapses, while the esketamine + SSRI group showed a slightly lower incidence of suicidal attempts.

2025-06-01·MOLECULAR NEUROBIOLOGY

Milnacipran and Vanillin Alleviate Fibromyalgia-Associated Depression in Reserpine-Induced Rat Model: Role of Wnt/β-Catenin Signaling

Article

作者: Kamel, Ahmed S ; Shahin, Nancy N ; Sadik, Nermin Abdelhamid ; Kamaly, Nour A

Abstract:

Fibromyalgia (FM) patients are highly susceptible to depression. Wnt/β-catenin signaling has shown a crucial role against depression in several studies. The FDA-approved FM drug, milnacipran (Miln), has shown antinociceptive potential against FM. Yet, no study has investigated its antidepressant potential in FM. Vanillin (Van), a well-known phytochemical often employed as flavoring agent, has been previously reported for its antidepressant and antinociceptive effects in several animal models, but has not been tested so far in FM. This study explored the antidepressant effect of Van and Miln in FM through investigating Wnt/β-catenin signaling. FM was induced in female Wistar rats by injecting reserpine (1 mg/kg/day s.c) for 3 days. Thereafter, animals received either Miln (30 mg/kg/day p.o) or Van (100 mg/kg/day p.o) for the subsequent 14 days. Results showed that both drugs demonstrated antidepressant effect in forced swimming test besides analgesic, and antiallodynic influences observed in Randall-Selitto, hot plate, cold allodynia, Von-Frey, and tail immersion tests. Biochemically, Miln and Van significantly enhanced serotonergic transmission in the hippocampus and upregulated the protein expression of the Wnt/GSK-3β/β-catenin signaling axis, including the downstream proteins, T cell factor, and dicer. This is followed by subsequent upregulation of the resilience micro ribonucleic acids (miRNAs) 124 and 135. Histopathological examinations corroborated the biochemical and molecular findings. Interestingly, these effects of Miln and Van were overturned via administration of the β-catenin inhibitor, XAV939 (0.1 mg/kg, i.p., daily). In conclusion, this study outlined the antidepressant aptitude of Miln and Van through activating Wnt/β-catenin signaling in the hippocampus in reserpine-induced FM.

项与盐酸米那普仑相关的新闻（医药）

2025-08-31

·信狐药迅

上海欣峰2.2类吡仑帕奈口溶膜提交上市申请|新受理（8.25-8.31）

本周药品注册受理数据，分门别类呈现，一目了然。(8.25-8.31）新药上市申请药品名称企业注册分类受理号吡仑帕奈口溶膜上海欣峰制药有限公司 2.2 CXHS2500105 吡仑帕奈口溶膜上海欣峰制药有限公司 2.2 CXHS2500104 新药临床申请药品名称企业注册分类受理号 HH101785片上海海和药物研究开发股份有限公司 1 CXHL2500933 HH101785片上海海和药物研究开发股份有限公司 1 CXHL2500932 JNJ-88998377口服片强生(中国)投资有限公司 1 CXHL2500927 JNJ-88998377口服片强生(中国)投资有限公司 1 CXHL2500926 JNJ-88998377口服片强生(中国)投资有限公司 1 CXHL2500925 ANS014004片北京鞍石生物科技股份有限公司 1 CXHL2500920 ANS014004片北京鞍石生物科技股份有限公司 1 CXHL2500918 PLB1004胶囊鞍石药业(宁波)有限责任公司 1 CXHL2500900 PLB1004胶囊鞍石药业(宁波)有限责任公司 1 CXHL2500899 JMKX000189片上海济煜医药科技股份有限公司 1 CXHL2500924 JMKX000189片上海济煜医药科技股份有限公司 1 CXHL2500923 JMKX000189片上海济煜医药科技股份有限公司 1 CXHL2500922 XNW34017片苏州信诺维医药科技股份有限公司 1 CXHL2500921 XNW34017片苏州信诺维医药科技股份有限公司 1 CXHL2500919 ST-01156胶囊万春宏基(大连)医药有限公司 1 CXHL2500917 ST-01156胶囊万春宏基(大连)医药有限公司 1 CXHL2500916 ST-01156胶囊万春宏基(大连)医药有限公司 1 CXHL2500915 ST-01156胶囊万春宏基(大连)医药有限公司 1 CXHL2500914 BIOS-0625片杭州百诚医药科技股份有限公司 1 CXHL2500908 BIOS-0625片杭州百诚医药科技股份有限公司 1 CXHL2500907 SAL0140片深圳信立泰药业股份有限公司 1 CXHL2500898 SAL0140片深圳信立泰药业股份有限公司 1 CXHL2500897 SAL0140片深圳信立泰药业股份有限公司 1 CXHL2500896 HBW-012462片成都海博为药业有限公司 1 CXHL2500889 HBW-012462片成都海博为药业有限公司 1 CXHL2500888 SBK008注射液成都施贝康生物医药科技有限公司 1 CXHL2500887 P-0264直服颗粒华益泰康药业股份有限公司 2.2 CXHL2500930 JL4083吸入溶液四川健林药业有限责任公司 2.2 CXHL2500911 JL4083吸入溶液四川健林药业有限责任公司 2.2 CXHL2500910 JL4083吸入溶液四川健林药业有限责任公司 2.2 CXHL2500909 BIOS2242口服溶液浙江赛默制药有限公司 2.2 CXHL2500895 司美格鲁肽注射液齐鲁制药有限公司 2.2 CXHL2500906 司美格鲁肽注射液齐鲁制药有限公司 2.2 CXHL2500905 司美格鲁肽注射液齐鲁制药有限公司 2.2 CXHL2500903 司美格鲁肽注射液齐鲁制药有限公司 2.2 CXHL2500904 司美格鲁肽注射液齐鲁制药有限公司 2.2 CXHL2500901 盐酸奥洛他定口服液北京尚修堂医药科技有限公司 2.2 CXHL2500892 盐酸奥洛他定口服液北京尚修堂医药科技有限公司 2.2 CXHL2500891 硫酸艾玛昔替尼片江苏恒瑞医药股份有限公司 2.4 CXHL2500931 富马酸泰吉利定注射液江苏恒瑞医药股份有限公司 2.4 CXHL2500913 富马酸泰吉利定注射液江苏恒瑞医药股份有限公司 2.4 CXHL2500912 瑞维鲁胺片江苏恒瑞医药股份有限公司 2.4 CXHL2500890 TTYP01片上海澳宗生物科技有限公司 2.4;2.2 CXHL2500902 KEM2408乳胶内蒙古科立雅药业有限公司 2.4;2.2 CXHL2500894 KEM2408乳胶内蒙古科立雅药业有限公司 2.4;2.2 CXHL2500893 重组带状疱疹疫苗(CHO细胞) 北京科兴中维生物技术有限公司 1.3 CXSL2500749 注射用ZG006 苏州泽璟生物制药股份有限公司 1 CXSL2500753 注射用戈氏梭菌芽孢冻干粉施慧达药业集团(吉林)有限公司 1 CXSL2500752 9MW3811注射液迈威(上海)生物科技股份有限公司 1 CXSL2500751 SCTC21C注射液神州细胞工程有限公司 1 CXSL2500750 ARC001滴鼻液羿旻生物医药科技(东阳)有限公司 1 CXSL2500748 ARC001注射液羿旻生物医药科技(东阳)有限公司 1 CXSL2500747 AK152注射液中山康方生物医药有限公司 1 CXSL2500746 PM8002注射液百欧恩泰(上海)医药有限公司 1 CXSL2500744 PM8002注射液百欧恩泰(上海)医药有限公司 1 CXSL2500743 GenSci134注射液长春金赛药业有限责任公司 1 CXSL2500738 GenSci134注射液长春金赛药业有限责任公司 1 CXSL2500737 WSK-V108E 北京威斯克生物医药有限公司 1 CXSL2500736 WGc-0201 注射液成都威斯津生物医药科技有限公司 1 CXSL2500735 G01滴眼液青岛万明赛伯生物医药有限公司 1 CXSL2500742 G01滴眼液青岛万明赛伯生物医药有限公司 1 CXSL2500741 G01滴眼液青岛万明赛伯生物医药有限公司 1 CXSL2500740 G01滴眼液青岛万明赛伯生物医药有限公司 1 CXSL2500739 QT-019B细胞注射液杭州启函生物科技有限公司 1 CXSL2500745 仿制药申请药品名称企业注册分类受理号中性低钙腹膜透析液(碳酸氢盐-G2.5%) 海南爱科制药有限公司 3 CYHS2503187 中性低钙腹膜透析液(碳酸氢盐-G1.5%) 海南爱科制药有限公司 3 CYHS2503186 中性腹膜透析液(碳酸氢盐-G2.5%) 海南爱科制药有限公司 3 CYHS2503185 中性腹膜透析液(碳酸氢盐-G1.5%) 海南爱科制药有限公司 3 CYHS2503184 盐酸二甲双胍口服液安徽四环科宝制药有限公司 3 CYHS2503201 盐酸二甲双胍口服液安徽四环科宝制药有限公司 3 CYHS2503200 磷酸奥司他韦颗粒山东朗诺制药有限公司 3 CYHS2503199 磷苯妥英钠注射液武汉华尔生物科技有限公司 3 CYHS2503195 磷苯妥英钠注射液武汉华尔生物科技有限公司 3 CYHS2503194 复方聚乙二醇(3350)电解质口服溶液河北华晨药业集团有限公司 3 CYHS2503175 盐酸米那普仑片白云山东泰商丘药业有限公司 3 CYHS2503173 盐酸地尔硫䓬控释胶囊广州绿十字制药股份有限公司 3 CYHS2503164 地氯雷他定口服溶液千海始德堂(鹤壁)制药有限公司 3 CYHS2503163 地氯雷他定口服溶液千海始德堂(鹤壁)制药有限公司 3 CYHS2503162 盐酸异丙肾上腺素注射液辰欣药业股份有限公司 3 CYHS2503147 盐酸异丙肾上腺素注射液辰欣药业股份有限公司 3 CYHS2503146 盐酸利多卡因胶浆广东君康药业有限公司 3 CYHS2503138 盐酸利多卡因注射液山西铭羽生物科技有限公司 3 CYHS2503129 碳酸司维拉姆干混悬剂国药集团致君(深圳)坪山制药有限公司 3 CYHS2503127 右酮洛芬氨丁三醇口服溶液北京柏雅联合药物研究所有限公司 3 CYHS2503126 舒林酸片苏州朗科生物技术股份有限公司 3 CYHS2503125 硫酸长春新碱注射液吉斯美(武汉)制药有限公司 3 CYHS2503117 西甲硅油咀嚼片浙江远力健药业有限责任公司 3 CYHS2503116 注射用磷霉素钠汇禹远和(海南)药业有限公司 3 CYHS2503131 注射用磷霉素钠汇禹远和(海南)药业有限公司 3 CYHS2503130 左羟丙哌嗪口服溶液合肥华威药业有限公司 3 CYHS2503113 酒石酸西尼必利片江苏永安制药有限公司 4 CYHS2503191 对乙酰氨基酚缓释片南京正大天晴制药有限公司 4 CYHS2503190 乌帕替尼缓释片江苏和晨药业有限公司 4 CYHS2503189 阿帕他胺片无锡紫杉药业股份有限公司 4 CYHS2503188 盐酸阿莫罗芬搽剂中山万汉制药有限公司 4 CYHS2503183 蔗糖羟基氧化铁咀嚼片湖南明瑞制药股份有限公司 4 CYHS2503182 硫酸氨基葡萄糖胶囊海南全星制药有限公司 4 CYHS2503181 莫匹罗星软膏浙江康润制药有限公司 4 CYHS2503180 盐酸达泊西汀片国大(吉林)制药集团有限公司 4 CYHS2503179 盐酸达泊西汀片国大(吉林)制药集团有限公司 4 CYHS2503178 注射用氯诺昔康北京四环科宝制药股份有限公司 4 CYHS2503203 地塞米松棕榈酸酯注射液河南利华制药有限公司 4 CYHS2503202 沙库巴曲缬沙坦钠片云鹏医药集团有限公司 4 CYHS2503198 沙库巴曲缬沙坦钠片云鹏医药集团有限公司 4 CYHS2503197 沙库巴曲缬沙坦钠片云鹏医药集团有限公司 4 CYHS2503196 达格列净二甲双胍缓释片(III) 陕西君可力医药科技有限公司 4 CYHS2503193 达格列净二甲双胍缓释片(I) 陕西君可力医药科技有限公司 4 CYHS2503192 吸入用复方异丙托溴铵溶液鲁南贝特制药有限公司 4 CYHS2503165 硫酸氨基葡萄糖胶囊四川梓橦宫药业股份有限公司 4 CYHS2503177 瑞维那新吸入溶液洋浦京泰药业有限公司 4 CYHS2503176 盐酸二甲双胍片石家庄市华新药业有限责任公司 4 CYHS2503174 醋酸阿托西班注射液北京双鹭药业股份有限公司 4 CYHS2503172 美阿沙坦钾片南京正科医药股份有限公司 4 CYHS2503171 美阿沙坦钾片南京正科医药股份有限公司 4 CYHS2503170 注射用硫酸艾沙康唑北京海步医药科技有限公司 4 CYHS2503169 吗啉硝唑氯化钠注射液石药银湖制药有限公司 4 CYHS2503168 帕拉米韦氯化钠注射液珠海同源药业有限公司 4 CYHS2503167 帕拉米韦氯化钠注射液珠海同源药业有限公司 4 CYHS2503166 溴芬酸钠滴眼液湖北美林药业有限公司 4 CYHS2503161 艾拉莫德片合肥华威药业有限公司 4 CYHS2503158 阿替卡因肾上腺素注射液华夏生生药业(北京)有限公司 4 CYHS2503157 枸橼酸西地那非片湘北威尔曼制药股份有限公司 4 CYHS2503156 枸橼酸西地那非片湘北威尔曼制药股份有限公司 4 CYHS2503155 钆喷酸葡胺注射液海南倍特药业有限公司 4 CYHS2503154 钆喷酸葡胺注射液海南倍特药业有限公司 4 CYHS2503153 甘油磷酸钠注射液湖北天圣药业有限公司 4 CYHS2503151 盐酸二甲双胍缓释片山东诚康药业有限公司 4 CYHS2503150 瑞维那新吸入溶液华润双鹤利民药业(济南)有限公司 4 CYHS2503160 瑞维那新吸入溶液九华华源药业(桂林)有限公司 4 CYHS2503159 甲磺酸溴隐亭片浙江泰利森药业有限公司 4 CYHS2503148 盐酸曲唑酮缓释片重庆锐恩医药有限公司 4 CYHS2503145 盐酸曲唑酮缓释片重庆锐恩医药有限公司 4 CYHS2503144 盐酸氨溴索注射液西洲医药科技(浙江)有限公司 4 CYHS2503143 盐酸氨溴索注射液西洲医药科技(浙江)有限公司 4 CYHS2503142 盐酸氨溴索注射液西洲医药科技(浙江)有限公司 4 CYHS2503140 伊曲康唑口服液湖北莱康医疗技术有限公司 4 CYHS2503139 玻璃酸钠滴眼液广州白云山天心制药股份有限公司 4 CYHS2503137 玻璃酸钠滴眼液广州白云山天心制药股份有限公司 4 CYHS2503136 阿达帕林凝胶北京京丰制药(河北)有限公司 4 CYHS2503135 莫匹罗星软膏遂成药业股份有限公司 4 CYHS2503134 阿帕他胺片海南卓泰制药有限公司 4 CYHS2503133 磷酸奥司他韦胶囊湖北远大永晟药业有限公司 4 CYHS2503149 艾拉莫德片宜昌东阳光长江药业股份有限公司 4 CYHS2503152 尼可地尔片山东新时代药业有限公司 4 CYHS2503128 阿达帕林过氧苯甲酰凝胶杭州和泽坤元药业有限公司 4 CYHS2503124 钆特酸葡胺注射液成都克莱蒙医药科技有限公司 4 CYHS2503123 甘油磷酸钠注射液浙江同伍生物医药有限公司 4 CYHS2503122 注射用磷酸左奥硝唑酯二钠仁合益康汇泽药业河北有限公司 4 CYHS2503121 聚多卡醇注射液成都倍特药业股份有限公司 4 CYHS2503120 聚多卡醇注射液成都倍特药业股份有限公司 4 CYHS2503119 聚多卡醇注射液成都倍特药业股份有限公司 4 CYHS2503118 腺苷注射液扬州中宝药业股份有限公司 4 CYHS2503115 腺苷注射液扬州中宝药业股份有限公司 4 CYHS2503114 聚乙二醇4000散武汉同济现代医药科技股份有限公司 4 CYHS2503132 阿帕他胺片郑州德迈药业有限公司 4 CYHS2503141 多替诺雷片天地恒一制药股份有限公司 4 CYHS2503112 注射用甲苯磺酸奥马环素海南卫康制药(潜山)有限公司 4 CYHS2503111 盐酸达利雷生片海南先声药业有限公司 4 CYHS2503110 盐酸达利雷生片海南先声药业有限公司 4 CYHS2503109 SHR0302碱凝胶瑞石生物医药有限公司 2.1;2.4;2.2 CXHL2500929 SHR0302碱凝胶瑞石生物医药有限公司 2.1;2.4;2.2 CXHL2500928 酮洛芬贴剂湖南华纳大药厂股份有限公司 3 CYHL2500157 注射用醋酸亮丙瑞林微球上海恒瑞医药有限公司 3 CYHL2500159 利多卡因丁卡因乳膏北京逸诚医药科技有限公司 3 CYHL2500154 利多卡因丁卡因乳膏北京逸诚医药科技有限公司 3 CYHL2500153 枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司 3 CYHL2500152 枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司 3 CYHL2500151 枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司 3 CYHL2500150 枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司 3 CYHL2500149 克霉唑阴道片浙江众延医药科技有限公司 4 CYHL2500158 茚达特罗格隆溴铵吸入粉雾剂广州呼吸药物工程技术有限公司 4 CYHL2500155 进口申请药品名称企业注册分类受理号维生素K1混合胶束注射液 CHEPLAPHARM Arzneimittel GmbH 5.1 JXHS2500091 注射用Rurioctocog alfa pegol Takeda Canada Inc 3.1 JXSS2500115 注射用Rurioctocog alfa pegol Takeda Canada Inc 3.1 JXSS2500114 注射用Rurioctocog alfa pegol Takeda Canada Inc 3.1 JXSS2500113 注射用Rurioctocog alfa pegol Takeda Canada Inc 3.1 JXSS2500112 注射用Rurioctocog alfa pegol Takeda Canada Inc 3.1 JXSS2500111 盐酸奥洛他定滴眼液 Teika Pharmaceutical Co., Ltd. 5.2 JYHS2500042 [111In]In-FL-020注射液 Full-Life Technologies GmbH 1 JXHL2500249 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500248 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500247 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500246 [225Ac]Ac-FL-020注射液 Full-Life Technologies GmbH 1 JXHL2500250 MK-0616 片 Merck Sharp & Dohme LLC 1 JXHL2500245 Orforglipron片 Eli Lilly and Company 1 JXHL2500243 Orforglipron片 Eli Lilly and Company 1 JXHL2500242 Orforglipron片 Eli Lilly and Company 1 JXHL2500241 Orforglipron片 Eli Lilly and Company 1 JXHL2500240 Orforglipron片 Eli Lilly and Company 1 JXHL2500239 Orforglipron片 Eli Lilly and Company 1 JXHL2500238 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500237 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500236 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500235 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500234 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500233 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500232 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500231 Brenipatide注射液 Eli Lilly and Company 1 JXHL2500230 DS-3201b片 Daiichi Sankyo, Inc. 2.4 JXHL2500244 英克司兰钠注射液 Novartis Pharma AG 2.4 JXHL2500229 AZD0486 AstraZeneca AB 1 JXSL2500160 AZD0486 AstraZeneca AB 1 JXSL2500159 AZD0486 AstraZeneca AB 1 JXSL2500158 AZD0486 AstraZeneca AB 1 JXSL2500157 萨特利珠单抗注射液 F. Hoffmann-La Roche Ltd. 2.2 JXSL2500164 萨特利珠单抗注射液 F. Hoffmann-La Roche Ltd. 2.2 JXSL2500163 Amivantamab注射液(皮下注射) Janssen Research & Development, LLC 2.2 JXSL2500162 Amivantamab注射液(皮下注射) Janssen Research & Development, LLC 2.2 JXSL2500161 中药相关申请药品名称企业注册分类受理号保精片苏中药业集团股份有限公司 1.1 CXZL2500069 痰火丸上海凯宝药业股份有限公司 1.1 CXZL2500068 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市

2025-08-15

·FiercePharma

With FDA nod, Tonix's Tonmya becomes first new fibromyalgia treatment in more than 16 years

An FDA approval for Tonix Pharmaceuticals' Tonmya makes it the first new medication for fibromyalgia in more than 16 years. Tonix Pharmaceuticals was founded in 2010 to develop and bring to market a drug for fibromyalgia. Fifteen years later, the New Jersey company has accomplished its mission with the FDA's endorsement of a new treatment for the painful chronic condition. The U.S. regulator’s green light covers first-in-class Tonmya (cyclobenzaprine HCl), which Tonix formulated as a once-daily bedtime treatment taken under the tongue for rapid absorption into the bloodstream. Tonmya marks the first new medicine approved for fibromyalgia in more than 16 years.“I’ve been working on this particular idea for more than 25 years,” Seth Lederman, Tonix’s CEO and co-founder, said in an interview with Fierce. “It’s a very hard condition to study and that’s why we’re so excited to finally be at the end.”The approval came after market close on Friday, but in the last few days, Tonix’s share price has increased by more than 10% in anticipation of the approval. The first three non-opioid drugs for fibromyalgia—Pfizer’s Lyrica, Eli Lilly’s Cymbalta and AbbVie’s Savella—were approved in a rapid-fire span of 19 months starting in 2007. Since then, there have been no non-opioid advancements in the treatment of the disorder, which primarily affects women.As a tertiary amine cyclic, Tonmya offers a new mechanism of action by targeting the nonrestorative sleep associated with fibromyalgia, as opposed to treating symptoms of the disease. While anticonvulsant Lyrica reduces pain signals sent to the brain, serotonin-norepinephrine reuptake inhibitors (SNRIs) Cymbalta and Savella affect brain chemistry, relieving depression and anxiety.Tonix has had a bumpy ride in its development of Tonmya, with two phase 3 successes sandwiched around a late-stage failure in 2023 to relieve pain in patients with fibromyalgia-type long COVID.Facilitating the approval were the two successful studies, which included nearly 1,000 patients. Across both trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, succeeding on the studies' primary endpoint. Additionally, a greater percentage of study participants taking Tonmya achieved a clinically meaningful 30% or better improvement in their pain after three months, when compared to placebo.The key advantage for Tonmya over other approved treatments is its sublingual delivery, which “is is designed to reduce pain quickly and durably with a tolerable safety profile," Andrea Chadwick, M.D., of the University of Kansas Health System, said in a statement accompanying Tonix's approval announcement. “Treatments that are processed through the liver can result in metabolites that could affect a medicine’s efficacy and safety over time,” she said.For now, Tonix plans to market Tonmya itself and will add 70 sales reps to its current staff of 10. Tonix also markets two migraine products which it acquired in 2023. The company has not yet announced what it will charge for Tonmya. “Our approach is to be flexible, see what works, what doesn’t work,” Lederman said during the interview. “We do believe that this could be—maybe should be—a big pharma drug. But we’ve also seen that the trend in the industry is that more and more—particularly in the [central nervous system] space—that companies have to launch the drug themselves.”The company will target the 3 million people in the U.S. who have been diagnosed with fibromyalgia. But a larger population awaits as epidemiology studies indicate that there are roughly 7 million others in the U.S. who have the disorder and who have not been identified.Developing TonmyaTonix’s approach to finding a treatment traces back 50 years, when Canadian psychologist Harvey Moldofsky suggested that fibromyalgia was more a sleep disorder than a pain issue.“It was an audacious proposal,” Lederman said. “But he was the inspiration for us to pursue sleep quality as a target of therapy. I do think that people with fibromyalgia will recognize that pain and sleep have a vicious cycle. It’s self-reinforcing: Bad sleep, worse pain. Worse pain, worse sleep.” Tonmya is a repurposed version of cyclobenzaprine, a muscle relaxant which Merck gained approval for in 1977. The company later tested it for fibromyalgia. While the molecule showed initial effectiveness for patients, cyclobenzaprine’s benefits faded over time and Merck discontinued the program.“Instead of looking at is as the glass is half empty, we looked at it as the glass is half full,” Lederman said. “We took that and said, ‘How do we engineer this and get something that will have durability?”Tonix did that by converting the treatment from a pill to a sublingual formulation. In 2010, Jazz Pharmaceuticals failed in its attempt to gain an FDA nod to treat fibromyalgia with its sleep treatment Xywav, which was later approved for narcolepsy and hypersomnia.The failures and triumphs have combined to shed more light on the often-misunderstood disorder, giving patients more reason to explore treatment options.“There used to be a thing, doctors saying fibromyalgia doesn’t exist, it’s just women complaining—all these kind of stereotypes, tropes if you will,” Lederman said. “At the [International Association for the Study of Pain conference] last year, fibromyalgia was the plenary session. Fibromyalgia has arrived and now we hopefully have a next-generation, first-in-class product to address it with better tolerability.”

临床结果上市批准临床3期

2025-07-18

·米内网

91亿创新高！抗抑郁药TOP20曝光，独家品种暴涨99%，翰森、科伦亮眼，32款1类新药蓄势

精彩内容近日，第十一批集采药品名单出炉，马来酸氟伏沙明片、阿戈美拉汀片2款抗抑郁化药在列。米内网数据显示，2024年中国公立医疗机构终端抗抑郁化药销售额拿下创新高的超91亿元；一级集团TOP20方面，翰森、京卫等强势领跑；产品TOP20中，草酸艾司西酞普兰片稳居榜首，独家1类新药暴涨99.92%；品牌TOP20中，翰森的阿戈美拉汀片蝉联桂冠，科伦、华海等上榜品牌亮眼。石药、绿叶、东阳光药......32款国产抗抑郁1类化药新药全速推进。91亿市场创新高！翰森、灵北、华海领跑抑郁症是目前全球第四大疾病，据《2023年中国抑郁症蓝皮书》显示，我国抑郁症患者已突破9500万人，占全球患者人数的三分之一。在中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端，抗抑郁化药销售额从2013年的约40亿元逐年攀升至2019年的超90亿元；随后受集采及疫情影响，2020-2022年销售额均出现不同程度的下滑；直至2023年市场止跌回升，销售额同比增长4.12%；2024年更拿下创新高的超91亿元销售佳绩，同比增长6.01%。近年来中国公立医疗机构终端抗抑郁化药销售趋势（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局抗抑郁化药是精神兴奋类化药中的王牌选手，2024年市场占比达60%，稳居TOP1宝座；从剂型上看，片剂、胶囊剂及溶液剂销售额均实现同比正增长，其中片剂为主力军，市场份额超过85%。2024年中国公立医疗机构终端精神兴奋化药小类销售格局来源：米内网中国公立医疗机构药品终端竞争格局一级集团销售额TOP20方面，灵北、翰森制药、晖致、山东京卫制药、华海药业依次位列前五。14个集团销售额实现正增长，其中国药集团大涨63.52%，海南合瑞制药大涨24.57%，华海药业、新和成、晖致均涨超15%，灵北、健康元药业、翔宇药业、复星医药均涨逾11%。2024年中国公立医疗机构终端抗抑郁化药一级集团TOP20注：增长率不足5%用*表示来源：米内网中国公立医疗机构药品终端竞争格局抗抑郁药TOP20！这款独家品种涨超99%抗抑郁药产品TOP20中，草酸艾司西酞普兰片自2015年起一直稳居榜首，2024年更以创新高的超19亿元销售额强势领跑；盐酸舍曲林片攀升至第二，销售额超9亿元；阿戈美拉汀片、马来酸氟伏沙明片和盐酸曲唑酮片分别排在第三、第四和第五。TOP5产品合计市占比超过55%。14个产品销售额实现正增长，其中山东绿叶制药的独家1类新药盐酸托鲁地文拉法辛缓释片暴涨99.92%，盐酸米那普仑片大涨78.07%，盐酸文拉法辛胶囊大涨28.73%，草酸艾司西酞普兰片、盐酸舍曲林片、盐酸帕罗西汀片、盐酸文拉法辛缓释胶囊及盐酸米安色林片分别涨逾11%。6个产品销售额出现负增长，其中第八批集采品种米氮平片下滑39.42%，第九批集采品种盐酸帕罗西汀肠溶缓释片、第五批集采品种盐酸文拉法辛缓释片均下跌10%以上。2024年中国公立医疗机构终端抗抑郁化药产品TOP20来源：米内网中国公立医疗机构药品终端竞争格局抗抑郁药品牌TOP20中，翰森制药集团的阿戈美拉汀片再度蝉联桂冠，实力不俗；山东京卫制药的草酸艾司西酞普兰片以超7亿元的销售额位居第二；灵北的草酸艾司西酞普兰片、晖致的盐酸舍曲林片相继排名第三和第四；丽珠集团丽珠制药的马来酸氟伏沙明片位列第五，销售额约4.4亿元。17个品牌销售额实现正增长，合计市占比约74%；其中，上海现代制药的盐酸米那普仑片大涨78.07%，四川科伦药业的氢溴酸西酞普兰片、北京福元医药的盐酸文拉法辛缓释胶囊、浙江华海药业的盐酸舍曲林片、仁和堂药业的盐酸米安色林片、灵北的草酸艾司西酞普兰片等10个品牌均涨逾11%。从企业层面上看，四川科伦药业、浙江华海药业、灵北各有2个品牌上榜。集采推动仿制原研替代，四川科伦药业上榜的2个产品草酸艾司西酞普兰片、氢溴酸西酞普兰片，以及浙江华海药业上榜的2个产品盐酸帕罗西汀片、盐酸舍曲林片均为国采中标品种。2024年中国公立医疗机构终端抗抑郁化药品牌TOP20注：增长率不足5%用*表示来源：米内网中国公立医疗机构药品终端竞争格局32款1类新药蓄势待发，石药、绿叶、东阳光药火力全开伴随社会对抑郁症患者的愈发重视，以及临床用药需求的不断提升，国内药企布局抗抑郁药物的热情持续高涨。米内网数据显示，今年以来，国内已有40个抗抑郁药（按产品批文统计）获批上市，包括科伦药业的阿戈美拉汀片、人福医药的琥珀酸地文拉法辛缓释片、石家庄四药的氢溴酸伏硫西汀片和马来酸氟伏沙明片、青峰医药的盐酸曲唑酮片等。2025年以来获批上市的抗抑郁药来源：米内网中国申报进度（MED）数据库40个抗抑郁药涉及11个品种，其中氢溴酸伏硫西汀片、盐酸度洛西汀肠溶胶囊、盐酸文拉法辛缓释胶囊等为已纳入国采品种，获批企业数均达12家及以上；马来酸氟伏沙明片、阿戈美拉汀片各有21家和16家国内企业获批上市、通过/视同通过一致性评价，并拟纳入第十一批国家药品集采，“光脚”企业可借助集采中标抢占市场。另有2个品种获批企业数在5家以内，其中琥珀酸地文拉法辛缓释片仅2家企业获批生产，石药集团、人福医药先后冲线并视同过评；草酸艾司西酞普兰口服溶液有4家企业拥有生产批文，倍特药业、山东朗诺制药、江苏长泰药业等10家企业均以新分类报产在审，获批即视同过评。与此同时，高度拥挤的仿制药赛道，叠加集采“大杀价”的影响，众多本土药企已纷纷把目光投向抗抑郁创新药的开发上。据米内网统计，针对抑郁症，国内已有至少32款国产抗抑郁1类化药新药处于获批临床及以上阶段，涉及绿叶制药、石药集团、东阳光药、翰森制药、华海药业、恩华药业、天士力、上海医药等20余家药企。国产抗抑郁1类化药新药在研情况来源：米内网综合数据库32款国产抗抑郁1类化药新药中，绿叶制药的盐酸托鲁地文拉法辛缓释片于2022年11月获批上市，实现国产抗抑郁创新化药“零”的突破；石药集团的盐酸阿姆西汀肠溶片、吉贝尔药业的JJH201501片均处于Ⅲ期临床，东阳光药的磷酸嘧替佐酮片处于Ⅱ/Ⅲ期临床，上市可期。此外，信立泰的SAL0114片、华海药业的盐酸羟哌吡酮片、翰森制药的HS-10353胶囊、天士力的JS1-1-01片、康弘药业的KH607片等13款新品已步入Ⅱ期临床，研发赛道日趋火热。资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至7月18日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

带量采购医药出海

100 项与盐酸米那普仑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01107	盐酸米那普仑	N06AX17	DB04896

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
纤维肌痛	美国	AbbVie, Inc.	2009-01-14
抑郁症	日本	Pierre Fabre SA	1999-09-22
抑郁症	日本	Asahi Kasei Corp.	1999-09-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疲劳	临床3期	美国	Forest Laboratories LLC	2011-07-01
神经痛	临床3期	美国	Forest Laboratories LLC	2011-04-05
外阴前庭炎	临床3期	美国	Forest Laboratories LLC	2010-10-01
外阴痛	临床3期	美国	Forest Laboratories LLC	2010-10-01
背痛	临床3期	美国	Forest Laboratories LLC	2010-08-01
肠易激综合征	临床2期	美国	Forest Laboratories LLC	2012-04-01
腰痛	临床2期	美国	Forest Laboratories LLC	2010-10-01
痛觉过敏	临床1期	美国	Forest Laboratories LLC	2009-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01393522 (CTgov)	N/A	疼痛 \| 偏头痛 \| 头痛	37	Milnacipran (Milnacipran)	網蓋製壓構築鏇憲鑰憲(淵壓餘觸憲夢窪網鑰廠) = 範願蓋壓遞遞鏇願醖鏇積憲憲繭壓鏇築鹹艱艱 (糧蓋夢繭壓遞餘選窪鹹, 壓製顧醖糧膚獵糧窪鏇 ~ 範顧鬱鏇觸網廠廠願繭) 更多	-	2022-08-12
				Placebo (Placebo)	網蓋製壓構築鏇憲鑰憲(淵壓餘觸憲夢窪網鑰廠) = 窪糧膚顧鏇憲餘齋範鏇積憲憲繭壓鏇築鹹艱艱 (糧蓋夢繭壓遞餘選窪鹹, 範蓋醖蓋願廠壓鹹鏇遞 ~ 鬱觸積膚範壓顧淵鹹鹽) 更多
NCT01288937 (CTgov)	临床3期	疼痛 \| 神经痛 \| 周围神经系统疾病	6	Milnacipran (Milnacipran)	積鬱糧獵窪鑰廠窪範鏇(淵壓製顧鏇製築繭構顧) = 鏇顧積醖構餘觸鏇膚繭憲齋繭蓋蓋鏇鬱餘築齋 (鹹壓築窪廠鏇糧廠築顧, 鏇簾獵艱壓遞繭餘鏇醖 ~ 夢窪鹽糧鏇鹹夢襯築製) 更多	-	2020-09-03
				Placebo (Placebo)	積鬱糧獵窪鑰廠窪範鏇(淵壓製顧鏇製築繭構顧) = 鹽構齋衊艱糧積網鏇鬱憲齋繭蓋蓋鏇鬱餘築齋 (鹹壓築窪廠鏇糧廠築顧, 顧鹽鑰鏇選壓觸遞積願 ~ 築鹽壓廠築憲選醖積艱) 更多
NCT01337700 (CTgov)	临床4期	自闭症谱系障碍 \| 自闭症 \| 阿斯伯格综合症	10	Milnacipran (Milnacipran)	網網獵糧膚鹽淵願觸襯(願簾遞築醖壓築壓鏇淵) = 淵艱餘憲憲鑰網願襯範窪觸簾壓遞淵簾顧鹽衊 (範獵膚鏇鏇選獵鏇窪醖, 14.83) 更多	-	2020-02-27
				Placebo (Placebo)	網網獵糧膚鹽淵願觸襯(願簾遞築醖壓築壓鏇淵) = 蓋夢選憲顧鏇衊夢壓膚窪觸簾壓遞淵簾顧鹽衊 (範獵膚鏇鏇選獵鏇窪醖, 5.81) 更多
NCT01288807 (Forest, CTgov)	临床4期	疼痛 \| 纤维肌痛	8	Milnacipram	鬱醖簾簾獵淵網膚鹹觸(選襯繭襯鏇壓壓齋憲窪) = 觸選鹽窪餘顧淵襯鏇餘衊網鏇膚膚齋網齋艱製 (衊製廠餘醖選淵獵鑰餘, 26.2) 更多	-	2019-09-24
NCT01328002 (MyFi, CTgov)	临床2期	纤维肌痛	116	Placebo (Placebo)	顧夢範糧餘鏇憲構繭窪(淵網膚鬱蓋窪遞醖願憲) = 獵願鹽積淵獵襯艱齋壓壓醖夢鑰淵壓餘壓願膚 (遞憲願壓齋廠窪齋製鹽, NA) 更多	-	2019-05-14
				Milnacipran (Milnacipran)	顧夢範糧餘鏇憲構繭窪(淵網膚鬱蓋窪遞醖願憲) = 鹹鑰壓鑰艱鬱夢鹽鑰齋壓醖夢鑰淵壓餘壓願膚 (遞憲願壓齋廠窪齋製鹽, 1.4) 更多
NCT01294059 (Pubmed \| J Pain) 人工标引	临床1期	疼痛 \| 纤维肌痛 \| 痛觉过敏	46	milnacipran	憲築蓋壓艱膚築淵繭繭(膚憲築衊艱鬱製願壓醖) = significantly declined by 15%, but this improvement was not statistically different between milnacipran and placebo 膚窪範窪夢築醖壓鹽壓 (膚鏇窪廠觸衊遞齋齋鏇 )	不佳	2015-08-01
				Placebo
NCT01234675 (CTgov)	临床4期	睡眠异常 \| 纤维肌痛 \| 睡眠	19	Milnacipran (Milnacipran)	壓鑰願鬱醖糧蓋艱製願(齋齋繭積夢襯衊築鏇夢) = 衊衊齋願壓築獵窪選積艱襯窪醖觸廠醖簾憲壓 (鹹膚衊積簾醖觸餘窪襯, 4.5) 更多	-	2015-07-22
				Placebo (Placebo)	壓鑰願鬱醖糧蓋艱製願(齋齋繭積夢襯衊築鏇夢) = 衊糧願襯選廠遞廠築壓艱襯窪醖觸廠醖簾憲壓 (鹹膚衊積簾醖觸餘窪襯, 4.2) 更多
NCT01173055 (CTgov)	临床4期	疼痛 \| 纤维肌痛	22	milnacipran (Milnacipran)	醖築鬱鑰鏇鹹鬱膚壓鹹(顧齋淵簾憲窪膚鑰構醖) = 淵築齋簾觸糧膚餘鏇衊網觸製壓齋淵膚遞築窪 (願顧膚製鹽膚夢齋廠簾, .83166) 更多	-	2015-02-20
				Placebo (Placebo)	醖築鬱鑰鏇鹹鬱膚壓鹹(顧齋淵簾憲窪膚鑰構醖) = 願願網鏇鬱齋壓構艱鑰網觸製壓齋淵膚遞築窪 (願顧膚製鹽膚夢齋廠簾, .84339) 更多
NCT01510457 (KOA, CTgov)	临床4期	慢性疼痛 \| 膝关节炎	46	Milnacipran (Milnacipran)	製遞醖獵餘鏇鹹醖繭醖(膚窪齋製築鹽簾襯積鏇) = 壓齋膚鹹衊繭餘淵壓襯壓壓構製齋膚積範鹽繭 (網艱淵鬱艱鬱網夢選築, 7.3) 更多	-	2015-01-22
				Placebo (Sugar Pill)	製遞醖獵餘鏇鹹醖繭醖(膚窪齋製築鹽簾襯積鏇) = 餘顧積齋鏇淵範觸構構壓壓構製齋膚積範鹽繭 (網艱淵鬱艱鬱網夢選築, 12.2) 更多
NCT01207453 (CTgov)	临床4期	关节痛 \| 类风湿关节炎	49	placebo (Placebo)	鑰鹽觸餘願簾窪鹽鑰壓(繭鏇製夢鏇膚夢淵憲糧) = 淵襯夢鹽獵鹹衊願餘蓋膚憲鏇鑰壓獵構選製壓 (淵膚顧蓋餘願襯廠艱艱, 2.1) 更多	-	2014-11-17
				Milnacipran (Milnacipran)	鑰鹽觸餘願簾窪鹽鑰壓(繭鏇製夢鏇膚夢淵憲糧) = 鏇襯鹽構窪簾齋糧顧鏇膚憲鏇鑰壓獵構選製壓 (淵膚顧蓋餘願襯廠艱艱, 2.0) 更多